Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2 : A Single-Center Retrospective Study in Saudi Arabia
© 2023. The Author(s)..
The outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality of transplant recipients. We reviewed the results of SARS-CoV-2 whole genome sequence of random isolates collected from 29 December 2021 until 17 May 2022 in King Faisal Specialist Hospital and Research center, Jeddah (KFSHRC-J), Saudi Arabia performed as hospital genomic surveillance program for COVID-19 variants. We included 25 transplant patients infected with confirmed Omicron variants.17 (68%) and 8 (32%) patients had Omicron BA.1 and BA.2, respectively. 12 (68%) patients had renal transplants. Only 36% of patients received three doses of COVID-19 vaccines. 23 (92%) patients required hospitalization. 20 (80%) patients survived and 6 (25%) required intensive care unit (ICU) admission. Among ICU patients, 66.7% were more than 50 years, 50% had two to three comorbidities and 5 out of 6 (83%) died. The mortality of transplant patients infected with Omicron variants in our cohort was higher than other centers as a limited number of patients received booster vaccines. Optimizing booster vaccination is the most efficient method to improve the mortality of COVID-19 in transplant recipients recognizing the inefficacy of monoclonal antibodies in the presence of SARS-CoV-2 emerging variants. We did not show a difference in mortality in transplant patients infected with Omicron BA.1 and BA.2 knowing the limitation of our sample size.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of epidemiology and global health - 13(2023), 1 vom: 10. März, Seite 47-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alshukairi, Abeer N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 05.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s44197-023-00084-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351371249 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351371249 | ||
| 003 | DE-627 | ||
| 005 | 20231226051215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s44197-023-00084-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351371249 | ||
| 035 | |a (NLM)36626091 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alshukairi, Abeer N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2 |b A Single-Center Retrospective Study in Saudi Arabia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 05.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a The outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality of transplant recipients. We reviewed the results of SARS-CoV-2 whole genome sequence of random isolates collected from 29 December 2021 until 17 May 2022 in King Faisal Specialist Hospital and Research center, Jeddah (KFSHRC-J), Saudi Arabia performed as hospital genomic surveillance program for COVID-19 variants. We included 25 transplant patients infected with confirmed Omicron variants.17 (68%) and 8 (32%) patients had Omicron BA.1 and BA.2, respectively. 12 (68%) patients had renal transplants. Only 36% of patients received three doses of COVID-19 vaccines. 23 (92%) patients required hospitalization. 20 (80%) patients survived and 6 (25%) required intensive care unit (ICU) admission. Among ICU patients, 66.7% were more than 50 years, 50% had two to three comorbidities and 5 out of 6 (83%) died. The mortality of transplant patients infected with Omicron variants in our cohort was higher than other centers as a limited number of patients received booster vaccines. Optimizing booster vaccination is the most efficient method to improve the mortality of COVID-19 in transplant recipients recognizing the inefficacy of monoclonal antibodies in the presence of SARS-CoV-2 emerging variants. We did not show a difference in mortality in transplant patients infected with Omicron BA.1 and BA.2 knowing the limitation of our sample size | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron variant | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Transplantation | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Aldabbagh, Yasser |e verfasserin |4 aut | |
| 700 | 1 | |a Adroub, Sabir A |e verfasserin |4 aut | |
| 700 | 1 | |a Mourier, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Abumelha, Khalid Y |e verfasserin |4 aut | |
| 700 | 1 | |a Albishi, Ghadeer E |e verfasserin |4 aut | |
| 700 | 1 | |a Alraddadi, Basem M |e verfasserin |4 aut | |
| 700 | 1 | |a Al Hroub, Mohammad K |e verfasserin |4 aut | |
| 700 | 1 | |a El-Saed, Aiman |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Suzan M Nagash |e verfasserin |4 aut | |
| 700 | 1 | |a Al Musawa, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Almasari, Ahlam |e verfasserin |4 aut | |
| 700 | 1 | |a Habahab, Wael T |e verfasserin |4 aut | |
| 700 | 1 | |a Alhamlan, Fatimah S |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Omari, Awad |e verfasserin |4 aut | |
| 700 | 1 | |a Pain, Arnab |e verfasserin |4 aut | |
| 700 | 1 | |a Dada, Ashraf |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of epidemiology and global health |d 2011 |g 13(2023), 1 vom: 10. März, Seite 47-54 |w (DE-627)NLM226225496 |x 2210-6014 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:10 |g month:03 |g pages:47-54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s44197-023-00084-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 10 |c 03 |h 47-54 | ||